Overview Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers Status: Completed Trial end date: 2008-05-01 Target enrollment: Participant gender: Summary To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers. Phase: Phase 2 Details Lead Sponsor: Eli Lilly and Company